Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice.

Autor: Pérez Cabeza AI; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., González Correa JA; Faculty of Health Sciences, University of Málaga, Málaga, Spain., Chinchurreta Capote PA; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., Bravo Marqués R; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., Ruiz Mateas F; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., Rosas Cervantes G; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., Mesa Prado F; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., López Tejero S; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain., Valle Alberca A; Department of Cardiology, Hospital Costa del Sol, Marbella, Spain.
Jazyk: angličtina
Zdroj: Future cardiology [Future Cardiol] 2018 May; Vol. 14 (3s), pp. 9-16.
DOI: 10.2217/fca-2018-0021
Abstrakt: Aim: To evaluate medication persistence and outcomes in patients with atrial fibrillation after 2 years of treatment with rivaroxaban in routine practice.
Methods: Retrospective study of atrial fibrillation patients in whom rivaroxaban was prescribed during the first quarter of 2014 in the healthcare area of Costa del Sol (Málaga).
Results: A total of 111 patients (mean age 74.9 ± 10.9 years; 52.3% men; CHA 2 DS 2 -VASc 3.6 ± 1.3; HAS-BLED 1.3 ± 0.6) were included. A total of 96.3 and 90.6% of patients remained on rivaroxaban therapy after 1 and 2 years of treatment, respectively. During this period, stroke, net clinical benefit outcome (thromboembolic events, myocardial infarction, cardiovascular death and major bleeding) and cardiovascular death occurred in 3.6, 5.4 and 1.8% of patients, respectively.
Conclusion: In routine practice, medication persistence with rivaroxaban was high. Rates of major cardiac events were low.
Databáze: MEDLINE
Externí odkaz: